1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Prescribing Information for Health Care Providers and Patient Labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; February 2004. Available at: http://www.fda.gov/cder/guidance/5670dft.doc. Accessed February 15, 2005.
2. Executive summary;Obstet Gynecol,2004
3. National use of postmenopausal hormone therapy;Hersh;JAMA,2004
4. Hormone therapy prescribing patterns in the United States;Buist;Obstet Gynecol,2004
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation[draft guidance]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; January 2003. Available at: http://www.fda.gov/cder/guidance/5412dft.doc. Accessed February 15, 2005.